← All trials
NCT05731219
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 26, 2022
- Primary completion
- Sep 26, 2023
- Completion date
- Sep 26, 2025
- First posted
- Feb 16, 2023
- Last posted
- Feb 16, 2023
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.Lead sponsor
- Zhejiang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.